How SLX4 cuts through the mystery of HIV-1 Vpr-mediated cell cycle arrest

Marie-Lise Blondot\textsuperscript{1,2,3}, Loïc Dragin\textsuperscript{1,2,3}, Hichem Lahouassa\textsuperscript{1,2,3} and Florence Margottin-Goguet\textsuperscript{1,2,3}\textsuperscript{*}

Abstract

Vpr is one of the most enigmatic viral auxiliary proteins of HIV. During the past twenty years, several activities have been ascribed to this viral protein, but one, its ability to mediate cell cycle arrest at the G2 to M transition has been the most extensively studied. Nonetheless, the genuine role of Vpr and its pathophysiological relevance in the viral life cycle have remained mysterious. Recent work by Laguette et al. (Cell 156:134-145, 2014) provides important insight into the molecular mechanism of Vpr-mediated G2 arrest. This study highlights for the first time how Vpr recruits the SLX4 endonuclease complex and how Vpr-induced inappropriate activation of this complex leads to G2 arrest. Here, we will discuss these findings in the light of previous work to show how they change the view of Vpr's mechanism of action. We will also discuss how these findings open new questions towards the understanding of the biological function of Vpr regarding innate immune sensing.

Keywords: HIV, Vpr, SLX4, Endonucleases, Innate immune response, Cell cycle, DNA repair

Introduction

HIV type 1 and type 2 primate lentiviruses encode a set of auxiliary proteins that differ between the two lentiviral lineages. Vpr, Nef and Vif are expressed by both the HIV-1/SIVcpz and HIV-2/SIVsmm lineages, while Vpu is specific to the former and Vpx to the latter. These auxiliary proteins play a crucial role at the host-virus interface by modulating the intracellular micro-environment in favor of viral infection and dissemination [1]. So far, much work conducted to decipher their mechanism of action has helped to understand the molecular steps faced by HIV during the viral life cycle. Most HIV auxiliary proteins use the same strategy, i.e. hijacking a ubiquitin ligase complex, to target cellular proteins, the so-called restriction factors, for proteasome-mediated degradation. This is how HIV-1 Vpu, Vif or HIV-2/SIVsmm Vpx counteract tetherin/BST-2, APOBEC3G and SAMHD1 respectively [2]. Each cellular target displays specific and potent antiviral activity; de facto, some in vitro systems, in which the restriction factor is expressed, can recapitulate the dependence of infection on the viral protein. Alike Vpu, Vif or Vpx, we and others have previously shown that HIV-1 Vpr is also able to recruit a ubiquitin ligase complex, but the significance of such an interaction has remained unknown [3].

Expression of Vpr in cycling cells triggers cell cycle arrest at the G2 phase, prior to mitosis. Vpr-mediated G2 arrest was revealed in 1995 by several groups [4-8] and represents the most widely described property of the viral protein. However, the biological significance of this activity towards infection has been unclear for years given that efficient viral replication does not require Vpr in dividing cells. Paradoxically, a lack of Vpr slightly affects viral infection in macrophages that do not divide [9-12], suggesting that Vpr-mediated cell cycle arrest is irrelevant to its role towards infection in these cells.

The recent study by Laguette and collaborators [13] provides new information on the G2-arrest mechanism induced by Vpr by highlighting its connection with the SLX4 endonuclease complex (SLX4com), and in addition, reports a potential anti-immune role for Vpr via this interaction.

Review

Hijacking DCAF1/VprBP in S-phase to induce cell cycle arrest at the G2/M transition

In an attempt to decipher the molecular mechanisms underlying Vpr-mediated G2 arrest, several studies have...
reported that this activity depends on the DNA damage checkpoint network. This pathway involves the activation of ATR (Ataxia Telangiectasia-mutated and Rad3-related) and Chk1 kinases and ends-up with the inactivation of the cyclinB-Cdk1 complex, which governs mitosis entry [14-19]. In cooperation with its downstream effectors, ATR preserves genome stability, in particular by helping stalled replication forks to proceed following genotoxic stress [20]. Vpr-mediated induction of replication stress was observed in transformed cell lines but also in primary CD4+ T cells and correlates with the accumulation of replication protein A, which binds single stranded DNA following replication stress [19]. In good agreement, the pathway used by Vpr was also shown to result from an S phase-dependent mechanism and to involve association of Vpr with chromatin [19,21-23]. Yet, the precise mechanism by which Vpr caused DNA replication stress and the role of this stress during the course of the infection has remained elusive.

In 2007, Vpr binding protein (VprBP), later on renamed DCAF1 for DDB1-Cul4A-associated factor 1 (DDB1: DNA damage-binding protein 1, Cul4A: Cullin 4A) was recognized as a critical host factor in the ability of Vpr to trigger cell cycle arrest [22,24-29]. Prior to this, DCAF1/VprBP was first identified as a cellular protein binding to Vpr with high affinity [30] and ten years after, characterized as an adaptor of DDB1-Cul4 ubiquitin ligases [31-34]. The data collectively obtained by the different groups supported a model [22,24-28] in which Vpr simultaneously recruits the Cul4A ubiquitin ligase through DCAF1 and a so far unknown cellular protein required for entry into mitosis. As a result, the Vpr target protein was supposed to be ubiquitinated and degraded to subsequently trigger G2 arrest. Vpr itself was predicted to escape from DCAF1-induced degradation and even to be stabilized by its association with the Cul4A-DDB1 ubiquitin ligase [35]. In view of the model of ubiquitin ligase hijacking for the benefit of the viral cycle, we and others have hypothesized that the function of Vpr was dependent on the degradation of a specific host protein rather than the resulting G2 arrest that could be a side effect in cycling cells. In this case, we expected the host target of Vpr to be a negative factor for viral replication [3]. For many investigators, identification of the host protein(s) targeted for degradation by Vpr became a priority toward understanding the genuine function of this viral protein.

**Revisiting Vpr-mediated G2 arrest mechanism within the context of SLX4**

Following tandem affinity purification, immunoprecipitation and mass spectrometry, Laguette et al. identified structure-specific endonucleases (SSEs), namely ERCC1-ERCC4/XPF and MUS81-EME1, together with the SLX4 scaffold protein as new Vpr interacting partners [13]. Glyceral gradient sedimentation and co-immunoprecipitation studies confirmed that SLX4 subunits, DCAF1 and Vpr assemble into a single complex. SLX4, also known as BTBD12, was renamed FANCP, when biallelic mutations in the SLX4 gene were associated with Fanconi anemia (FA), an autosomal recessive genetic disorder characterized by congenital abnormalities, bone marrow failure and cancer susceptibility [36-39]. SLX4 provides a molecular platform to form a complex (SLX4com) with several SSEs, ERCC1-ERCC4/XPF, MUS81-EME1, but also SLX1, and stimulates their activities to coordinate the repair of specific replication-born double strand breaks (DSBs) and collapsed replication forks [38-40]. MUS81-EME1 and SLX1 are specifically dedicated to the resolution of replication-induced X-shaped DNA structures, the so-called Holliday Junctions, during homologous recombination [41-43]. These SSEs are submitted to strict regulations along the cell cycle to ensure the formation of an active complex at the right time and subsequently the removing of inadequate DNA recombination intermediates before chromosome segregation [41,44-48] (Figure 1). Laguette et al. observed that Vpr induces a slight decrease in EME1 and MUS81 expression and an increase in the levels of polo-like kinase 1 (PLK1) and phospho-PLK1, a kinase that activates the endonuclease activity of EME1 through its phosphorylation [39,45]. In parallel, Vpr caused a remodeling of SLX4com through its association with phospho-EME1 and the DCAF1 ubiquitin ligase (Figure 1). Importantly, time course experiments led to the conclusion that Vpr-induced activation of SLX4com precedes G2/M arrest and is not a consequence of the cell cycle arrest per se. In addition, SLX4 purified in the presence of Vpr had increased cleavage activity toward radiolabelled DNA substrates as compared to the endonuclease in the absence of Vpr. Interestingly, Vpr-mediated increase of SLX4com activity was abolished when MUS81 expression was silenced. Importantly also, downregulation of SLX4, EME1 or MUS81 expression inhibited Vpr-mediated G2 arrest, which has been recently confirmed by Berger et al. [49]. Collectively, the data support a model in which Vpr induces the premature activation of SLX4com, leading to replication stress as asserted by the appearance of FANCD2 foci [50]. Consequently, the abnormal cleavage of DNA replication intermediates would presumably cause a G2 arrest. It is unclear yet whether this process is related to previous observations suggesting that Vpr induces double-strand breaks (DSB) formation or that MUS81 plays a role in the formation of such breaks in response to the inhibition of replication [51,52]. Moreover, the interaction of SLX4com with chromatin in the presence or not of Vpr remains to be evaluated.
The Vpr-binding protein DCAF1 was also present in association with SLX4 and this interaction was enhanced with Vpr. Given its role in Vpr-mediated G2 arrest, the role of DCAF1 in SLX4com activation was further investigated. Silencing of DCAF1 reduced the accumulation of PLK1 and Phospho-PLK1 seen in the presence of Vpr and inhibited the reduction in MUS81 levels. In addition, more ubiquitinated MUS81 species were detected with wt Vpr, by comparing with the DCAF1-binding deficient Vpr mutant (Q65R), which did not induce FANCD2 foci accumulation. Nonetheless, whether the proteasome pathway is involved in this process remains to be investigated with the use, for example, of proteasome inhibitors. Altogether the results suggest that Vpr uses DCAF1 for SLX4com activation and reduction of MUS81 levels.

Vpr-mediated downregulation of MUS81 expression seems relatively inefficient. One explanation could be that degradation occurs in a short window of cell cycle progression, just before G2/M, making it difficult to highlight in asynchronous cells. Moreover, how degradation of MUS81 intervenes in the process of SLX4com activation remains unclear. As a viral protein hijacking a ubiquitin ligase, Vpr was initially thought to trigger the degradation of an antiviral factor. Here, the ubiquitination and the downregulation of MUS81 by Vpr could lead to envision it as a potential antiviral factor counteracted by Vpr and whose degradation would lead to G2 arrest. However, this is not the case, MUS81 depletion does not mimic a G2 arrest phenotype and MUS81 or SLX4 depletion reduces viral infection, which indicates their positive role for the viral life cycle. Nonetheless, it is intriguing that MUS81 is both required for G2 arrest and also inactivated by Vpr through DCAF1. Further studies will help to understand the orchestration of these different events.

Though the SLX1 SSE does not co-purify with Vpr and SLX4, SLX1 seems to participate in Vpr-mediated G2 arrest. Indeed, depletion of SLX1 reduces the ability of Vpr to mediate G2 arrest. In addition, purified SLX4com isolated from Vpr expressing cells still processes SLX1 substrates. Of note, Vpr interacts with the SLX1 binding domain of SLX4, which may indicate that interaction of SLX4 with SLX1 and with Vpr are exclusive. These apparently contradictory findings may reflect that a series of complex and successive events are involved in Vpr-mediated SLX4 activation.

Recent work by Berger et al. further supports a role of SLX4, MUS81 and EME1 in Vpr-mediated G2 arrest [49]. Interestingly, SIV Vpr alleles competent for G2

**Figure 1** Model for Vpr-mediated G2 arrest through remodeling of the SLX4 complex. In a physiological context activation of the SLX4 complex (SLX4com) intervenes to allow the resolution of DNA replication intermediates, such as Holliday Junctions (HJ), found in collapsed replication forks after DNA replication (phases of SLX4 activation are symbolized by green arrows). This leads to a proper G2/M phase transition (left panel). HIV-1 Vpr protein interacts with SLX4 on its SLX1 binding domain, the CUL4A–DDB1–DCAF1 ubiquitin ligase and PLK1/p-PLK1. These interactions lead to MUS81 ubiquitination, and phosphorylation of EME1 by p-PLK1, resulting in aberrant activation of SLX4com. This inappropriate activation perturbs progression of ongoing replication forks (RF) in S phase and the resolution of abnormal DNA replication intermediates. As a consequence, cells arrest at the G2 phase of the cell cycle (right panel).
arrest in human cells interact with human SLX4, but not alleles incompetent for G2 arrest in those cells. SIV Vpr alleles competent for G2 arrest in Grivet cells, but not in human cells, interact with simian SLX4. This species-specificity in Vpr-mediated G2 arrest supports the idea of a central role of SLX4 in Vpr function.

Altogether the results by Laguette et al. support a model in which Vpr forces activation of the SLX4 complex, rather than supporting the previous model in which Vpr eliminates an antiviral factor. Nonetheless, we are tempted to put forward the hypothesis that the two models could be reconciled in a model in which Vpr would for example induce the degradation of an inhibitor of SLX4 activation that has potent antiviral activity.

Vpr and escape from immune sensing

Persistent viruses such as HIV are known to interfere with the overall immune host response [53]. The role of Vpr in this context has been studied by several groups. Namely, two reports have previously demonstrated that Vpr decreases the expression of IFNβ, an essential protein for interferon (IFN) beta production in response to viral infection [54,55]. Furthermore, numerous immunosuppressive activities of Vpr have been identified, including its capacity to perturb the Th1 lymphocytes activity or the Treg homeostasis [56,57]. Altogether, these studies highlight a new capacity of Vpr to participate in the viral persistence by hindering the appropriate cooperation between immune cells. In Laguette et al., deletion of Vpr induces a 2 to 3 fold increase of the expression of mRNA of the type 1 interferon response (IFNa, IFNb and Mxα) upon HIV-1 infection in HeLa cells, supporting the notion that Vpr could contribute to HIV-1 escape from innate immune sensing. Nonetheless, whether reduction in IFN-related mRNAs in the presence of Vpr is related to SLX4 remains difficult to assess since deletion of SLX4 or MUS81 alone leads to a huge increase of the same mRNAs. Interestingly though, the authors showed that HIV-1 DNA products of reverse transcription are pulled down with epitope-tagged SLX4 specifically in the presence of Vpr and that reduction of SLX4 expression leads to an increase in HIV-1 DNA levels. These results suggest that Vpr could help to escape immune sensing by inducing the digestion of viral DNA through SLX4com activation (Figure 2).

Surprisingly, the increase in HIV-1 DNA levels under SLX4 knock-down is not associated with an increase in HIV-1 infection, however it should be stressed that the forms accumulated under SLX4 knock-down are not fully characterized yet and could correspond to abortive products of reverse transcription. It is also puzzling that no RT product is detected in the SLX4 immunoprecipitate a few hours after infection as we could expect from previous studies [58]. Given the presence of SLX4 into the nucleus, its association with 1/2LTR circles or even proviruses would be worth to look at deeply.

In a model in which SLX4 would play a role in the escape from immune sensing by digesting viral DNA, depletion of SLX4 should reduce viral infection. Accordingly, cells from FANCP patients or MEF cells depleted for SLX4 displayed high levels of IFNα, IFNβ and Mxα mRNA and a decreased permissivity to viral transduction. Of note, the decrease in HIV-1 infection under SLX4 depletion was seen in patient samples but not in HeLa cells depleted for SLX4 or MUS81. Why the high increase in IFN-related mRNAs in HeLa cells does not correlate with an inhibition of HIV-1 transduction in these same cells is puzzling. In other circumstances, production of IFN inhibits HIV-1 transduction in single-cycle infection experiments, for instance following depletion of the TREX1 endonuclease [59]. Several hypotheses can account for the lack of effect of Vpr on HIV-1 infection in HeLa cells. Though an effect on IFN-related mRNA levels is detected, it is likely that this effect does not lead to efficient interferon production, as it could be the case in other primary cells. Alternatively, the production of IFN might be too weak to have a negative effect on single-round infection, but would be cumulative in a spreading infection using replicative viruses. In this setting also, it is likely that HeLa cells do not have all the connections that allow efficient IFN signaling for subsequent HIV-1 infection inhibition. Surprisingly, a recent report has provided evidence that HIV-1 Vpr induces Interferon-Stimulated Genes (ISG) and helps to activate innate immune response in non-infected macrophages [60]. These apparent discrepancies may result from the use of different cellular systems, non-infected macrophages versus infected HeLa cells. Further experiments by additional investigators will help to draw a clearer picture of what is going on under Vpr treatment in different cell types.

Previous work has demonstrated how a subset of Vpr proteins from lentiviruses lacking the auxiliary protein Vpx were still able to degrade the antiviral factor SAMHD1 as well as Vpx from HIV-2/SIVsmm/SIVmac [61-63]. Unlike SLX4, SAMHD1 modulates the DNA damage response [64]. Mutations of SAMHD1 are found in the Aicardi-Goutières syndrome (AGS), a rare autosomal recessive genetic encephalopathy characterized by high levels of IFN leading to chronic inflammation [65]. Several studies indicate that SAMHD1 limits proinflammatory cytokine production and immune detection [65-70]. Inhibition of the immune sensing of HIV-1 through SAMHD1 results from the dNTPase activity of the protein, which contributes to the removal of nucleotides essential for viral cDNA synthesis in myeloid cells and quiescent CD4+ T cells, but could also potentially results from its recently identified RNAse activity.
Nonetheless, HIV-2/SIVsmm/SIVmac and a subset of other lentiviruses have kept the ability to degrade SAMHD1, in order to increase dNTP levels for efficient reverse transcription, even at the expense of the possibility to escape immune detection. Strikingly, HIV-1 Vpr and HIV-2/SIVsmm Vpx seem to function in opposite directions with respect to immune sensing. Altogether, by having no Vpx but one Vpr, HIV-1 has significant assets to escape immune detection compared to HIV-2. In addition, HIV-2 capsid harbors a major determinant for viral cDNA sensing, while HIV-1 capsid has been shown to prevent sensing or even to bind specific cofactors to evade immune detection [78-80]. Differences in escape from immune sensing likely contribute to the different pathogenic outcomes associated with the two viruses, HIV-1 being far more pathogenic than HIV-2 [81].

Other host proteins than SAMHD1 contribute to limit the sensing of viral nucleic acids, including RNASEH2, which degrades DNA:RNA hybrids or TREX1, which eliminates viral DNA in excess [82-85]. Importantly, genes encoding for TREX1 and RNASEH2 are also mutated in the Aicardi-Goutière syndrome (AGS), highlighting how these proteins provide a link between autoimmunity and nucleic acid metabolism [62,63,86-88]. This is also supported by their capacity to control endogenous retrotransposition [89-91]. An interesting possibility is that endogenous retroelements, alike abnormal replication intermediates, could trigger the activation of SLX4, a mechanism that would in turn lead to chronic inflammation in FA disease.

Once activated, how does SLX4 distinguish “good DNA” that will lead to productive infection, from “bad DNA” that will be destroyed? Such a question has already been brought up regarding TREX1 [92]. One hypothesis is that only non-productive short DNA generated by errors during reverse transcription may be targeted by nucleases. Alternatively, access to the viral DNA may be governed by the stability of the capsid core that is implicated in the control of reverse transcription [93-95]. In any event, identification of immune sensors associated to this process...
should improve our understanding of how HIV-1 escapes from the innate immune response. Whether the recently identified DNA sensors of HIV are specifically recruited in the absence of Vpr but not in its presence should be further addressed [78,96,97].

Another intriguing question concerns the presence or not of a signature of positive selection in SLX4. Such signature characterizes restriction factors and corresponds to variations in their sequences at the interface with the viral protein, reflecting an evolutionary arms-race between the virus and its host [98]. Recent work has shown how these sequence variations contribute to host susceptibility to viral infection. Here regarding the interplay between Vpr and SLX4, we are facing a new situation since SLX4 is not an antiviral factor, but is rather beneficial for the virus. One may speculate that co-evolution would push SLX4 to avoid Vpr in order to restore an immune response, while Vpr would evolve to conserve its association with SLX4.

**Vpr, SLX4com and a cellular system relevant for Vpr’s study**

Future work should aim at elucidating whether Vpr provides an advantage to viral infection by activating SLX4. Thus, an important issue is to analyze whether the delta-Vpr HIV-1 virus is similarly infectious in cells depleted or not of SLX4 as the wt virus in SLX4+/− cells. The limiting factor in such study is the choice of a cellular system in which Vpr would clearly increase viral infection. So far, macrophages have represented an appropriate system, since in these cells, Vpr-deficient HIV-1 showed a slight replication defect [9-12]. In contrast to previous findings, one study has also reported that Vpr is able to enhance HIV-1 infection in peripheral blood mononuclear cells and dendritic cells [99]. More studies are needed to assess what is the best *in vitro* cellular model in which replication would depend on the presence of Vpr. In macrophages, the question of the presence of SLX4 and the associated nucleases has to be addressed before wondering whether Vpr-mediated enhancement of macrophage infection is linked to the activity of SLX4com. Of note, Zimmerman *et al.* previously found that HIV-1 Vpr fails to induce activation of the ATR pathway in macrophages, due to the lack of protein expression of at least ATR, Chk1 and Rad17 [19]. However, the question is still open regarding SLX4com. If SLX4 drives HIV-1 Vpr function in certain cell types such as macrophages, then, one would like to know whether differences of Vpr alleles to activate SLX4 correlate with different capabilities to help macrophage infection.

**Conclusions**

The study from Laguette *et al.* provides important insights into the mechanism of Vpr-mediated G2 arrest with the identification of SLX4com as a new functional partner of Vpr. This discovery also opens new avenues to understand the biological role for Vpr along the viral life cycle. The idea that HIV may have developed a protein to induce the degradation of its own viral DNA leads to the intriguing questions of how the virus can achieve the right balance between preservation of viral DNA synthesis and escape from immune sensing through viral DNA degradation. In recent years, immune sensing has taken on a growing role in our understanding of the battle between the virus and the cell, making it important to identify the molecular players at stake such as SLX4com. Research associated to other diseases, namely AGS and FA, will certainly benefit from these discoveries.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

FMG wrote the review. MLB, LD, HL conceived the illustrations and were involved in discussions and critical reading of the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

The authors fully apologize to those who have not been referenced. The authors greatly acknowledge Cecilia Ramirez and Claudine Pique for carefully reading this manuscript and providing constructive comments. This work was supported by grants from the “Agence Nationale de la Recherche sur le SIDA et les hépatites virales” (ANRS), Sidaction and “Fondation de France”, Fondation pour la Recherche Médicale (FRM). MLB received support from ANRS, HL from Sidaction, LD from the University Paris Descartes and the “Ministère de l’Enseignement Supérieur et de la Recherche”.

**Author details**

1. Inserm, U1016, Institut Cochin, Paris, France. 2. Cnrs, UMR8104, Paris, France. 3. Université Paris Descartes, Sorbonne Paris Cité, France.

Received: 19 March 2014 Accepted: 27 November 2014 Published online: 11 December 2014

**References**

1. Malim MH, Emerman M. HIV-1 accessory proteins—ensuring viral survival in a hostile environment. *Cell Host Microbe* 2008, 3:388–398.
2. Strebel K. HIV accessory proteins versus host restriction factors. *Curr Opin Virol* 2013, 3:692–699.
3. Ayinde D, Maudet C, Transy C, Margottin-Goguet F. Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? *Retrovirology* 2010, 7:35.
4. He J, Choe S, Walker R, Di Marzo P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. *J Virol* 1995, 69:6705–6711.
5. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. *J Virol* 1995, 69:6304–6313.
6. Planelles V, Bachelerie F, Jowett JB, Haiatip A, Xie Y, Banoooni P, Masuda T, Chen IS. Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. *J Virol* 1995, 69:5883–5889.
7. Re F, Braaten O, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. *J Virol* 1995, 69:6859–6864.
8. Rogel ME, Wu L, Emerman M: The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. *J Virol* 1995, 69:882–888.
9. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman R: Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpu, vpr, and nef: mutational analysis of a primary HIV-1 isolate. Virology 2019, 520:523–631.

10. Connor RJ, Chen BK, Choe S, Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type 1 in mononuclear phagocytes. Virology 1992, 206:335–944.

11. Eckstein DA, Sherman MP, Penn ML, Chin PS, de Noronha CM, Greene WC, Goldsmith MA: HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med 2001, 194:1407–1419.

12. Jacquot G, Le Rouzic E, David A, Mazzolini J, Bouchet J, Bouaziz S, Niedergang F, Pancino G, Benichou S: Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology 2007, 4:34.

13. Laguette N, Bregnard C, Hue P, Basbous J, Yatim A, Larroque M, Kirchoff F, Constantinou A, Sobhian B, Benkirane M: premature Activation of the SLX4 complex by Vpr Promotes G2/M Arrest and Escape from Innate Immune Sensing. Cell 2014, 156:134–145.

14. Andersen JL, Planelles V: The role of Vpr in HIV-1 pathogenesis. Curr HIV Res 2005, 3:43–51.

15. Lai M, Zimmerman ES, Planelles V, Chen J: Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol 2005, 79:15443–15451.

16. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V: Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 2003, 278:25879–25886.

17. Ward J, Davis Z, DeHart JL, Zimmerman E, Bosque A, Brunetta E, Mavilio D, Perrone M, Niedergang F, Pancino G, Benichou S: A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase dysfunction of the replication factor Cdt1. Mol Cell 2006, 23:797–721.

18. Le Rouzic E, Morel A, Ayinde D, Belaidouni N, Letienne J, Transy C, Margottin-Goutet F: assembly with the Cul4A-DDB1DDCA1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation. J Biol Chem 2008, 283:21686–21692.

19. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A: Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011, 43:142–146.

20. Stoepker C, Hain K, Schuster B, Hilhorst-Hofte JY, Roomans MA, Stettenpod J, Oosta AB, Eirich K, Korthof ET, Nieuwint AW, Jaspers NG, Bettecken T, Joorje H, Schneider D, Roux J, de Winter JP: SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011, 43:138–141.

21. Munoz JM, Hain K, Declais AC, Gardiner M, Toh GW, Sanchez-Pulido L, Heuckmann JM, Toth R, Macartney T, Eppink B, Kanaar R, Ponting CP, Lilley DM, Roux J: Coordination of structure-specific nuclease by human SLX4/BDT12 is required for DNA repair. Nat Cell Biol 2009, 11:116–127.

22. Svendsen JM, Smogorzewska A, Sowa NE, O’Connell BC, Gygi SP, Elledge SJ, Harper JW: Mammalian BDT1/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 2009, 138:633–77.

23. Fekari S, Scaglione S, Chawan C, Taylor ER, Tissier A, Coulon S, Dong M, Ruse C, Yates JR 3rd, Russell B, Fuchs RP, McGowan CH, Gaillard PH: human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonuclease. Cell 2009, 138:78–99.

24. Wyatt HD, Sarbajna S, Matos J, West SC: Coordinated actions of SLX1-SLX4 and MUS81-EME1 for Holliday junction resolution in human cells. Mol Cell 2013, 52:334–247.

25. Gamer E, Kim Y, Lach FP, Kottmann MC, Smogorzewska A: Human GEN1 and the SLX4-associated nucleases MUS81 and SLX1 are essential for the resolution of replication-induced Holliday junctions. Cell Rep 2013, 3:207–215.

26. Castor D, Nair N, Declais AC, Lachaud C, Toth R, Macartney T, Eppink B, Kanaar R, Ponting CP, Lilley DM, Roux J: cooperative control of hollliday junction resolution and DNA repair by the SLX1 and MUS81-EME1 nucleases. Mol Cell 2013, 52:221–233.

27. Dehe PM, Coulon S, Scaglione S, Shanahan P, Takedachi A, Wohlschlegel JA, Yates JR 3rd, Llorente B, Russell P, Gaillard PH: Regulation of Mus81-Eme1 Holliday junction resolution in response to DNA damage. Nat Struct Mol Biol 2013, 20:598–603.

28. Gallo-Fernandez M, Saugar I, Ortiz-Bazan MA, Vazquez MV, Tercero JA: Cell cycle-dependent regulation of the nucleosome of Mus81-Eme1/Mms4. Nucleic Acids Res 2012, 40:8325–8335.

29. Matus J, Blanco MG, Masiain S, Skelhel JM, West SC: Regulatory control of the resolution of DNA recombination intermediates during meiosis and mitosis. Cell 2011, 147:158–172.

30. Gallo-Fernandez M, Saugar I, Ortiz-Bazan MA, Vazquez MV, Tercero JA: Cell cycle-dependent regulation of the nucleosome of Mus81-Eme1/Mms4. Nucleic Acids Res 2011, 40:8943–8958.

31. Berger G, Lawrence M, Hue S, Neil SJ: G2/M cell cycle arrest correlates with primate lentiviral Vpr interaction with the SLX4 complex. J Virol 2014.

32. Kim H, D’Andrea AD: Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev 2012, 26:1393–1408.
51. Tachibana H, Shimura M, Nakai-Murakami C, Tokunaga T, Takizawa Y, Sata T, Kurumizaka H, Ishizaka Y: HIV-1 Vpr induces DNA double-strand breaks. Cancer Res 2006, 66:627–631.
52. Hanada K, Budowksza M, Davies SL, van Drunen E, Onizawa H, Beverloo HB, Maas E, Assers J, Hickson ID, Kanar R: The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. Nat Struct Mol Biol 2007, 14:1106–1110.
53. Liu B, Woltman AM, Janssen HL, Boonstra A: Modulation of dendritic cell function by persistent viruses. J Leukoc Biol 2009, 85:205–214.
54. Doeblin BP, Hiadik F, McNevin JP, McElrath MJ, Gale M: In human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009, 83:10395–10405.
55. Okumura A, Alice T, Lubovska B, Ezele H, Strebel K, Pitha PM: HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 2008, 373:85–97.
56. Majumder B, Venkatachari NJ, Srinivasan A, Ayyavoo V: Human herpesvirus 6 induces immune pathogenesis: spotlight on the role of viral protein R (Vpr). Curr HIV Res 2009, 7:169–177.
57. Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, Ishizaka Y, Ito M, Aihara K, An DS, Koyanagi Y: HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo. PLoS Pathog 2013, 9:e1003812.
58. Butler SL, Hansen MS, Bushman FD: DNA methylation of the human SAMHD1 promoter is associated with persistent HIV-1 replication. Genes Immun 2011, 12:209–215.
59. van Weissenbruch J, Kuzmin PS, Korkisch J, Keppler OT, Jovanovic P, Bortova I, van der Velden H, Alonso L, Rios J, Rench LA, Barbieri A, Zeller S, Zaborina Y, Bergers J: SAMHD1 restricts HIV-1 replication in human primary CD4+ T cells. Retrovirology 2012, 9:387.
60. McElrath MJ, Gale M: HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011, 460:379–382.
61. Laurou P, Davis KG, Farzan M, Jernigan RL, Elkon R, Priva A, Berman J, Zhu J, Schuurs-Hockstra A, Matsuoka S, Fackler OT, Keppler OT: SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012, 13:223–228.
62. Barxwell RD, Holland PJ, Holloway T, Perino FW: Aicardi-Goutieres Syndrome gene and HIV-1 restriction factor SAMHD1 is a DGTP-regulated deoxynucleotidyl triphosphohydrolase. J Biol Chem 2011, 286:43596–43600.
63. Ryoo J, Choi O, Oh C, Kim S, Lee M, Kim J, White TE, Brandt-Stuehler AC, Nuñez A, Diaz-Giraffa F, Yun CH, Hollenbaugh JA, Kim S, Baek D, Ahn K: The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat Med 2014, 20:936–941.
64. Lahaye X, Sato T, Gentili M, Cerboni S, Conrad C, Hurban I, El Marjou A, Lacaerabatz C, Lelievre JD, Manel J: The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity 2013, 39:1132–1142.
65. Basraieh J, Tan CP, Fletcher AJ, Price AJ, Blondel A, Hillich L, Jacques DA, Selwood DL, James LC, Noursadeghi M, Towers GJ: HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 2013, 503:402–405.
66. Lancar Dru N: The innate immune response to HIV-1: to sense or not to sense? Nat Rev Immunol 2007, 7:169–176.
67. Rowland-Jones SL, Whittle HC: Out of Africa: what can we learn from the gene encoding the 3’-5’ cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 2013, 341:903–906.
68. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambell I, Wabnitz G, Gramberg T, Pantis N, Flory E, Landau NR, Sertel S, Rutsch F, Lasaichikla F, Kim B, König R, Fackler OT, Keppler OT: SAMHD1 restricts HIV-1 infection in resting CD4+ T cells. Nat Med 2012, 18:1682–1689.
69. Yokogawa N, Flack R, Tchiguinsetv A, Brown G, Popovic A, Nocek B, Yokunog AW: Nuclear Activity of the Human SAMHD1 Protein Implicated in the Aicardi-Goutieres Syndrome and HIV-1 Restriction. J Biol Chem 2013, 288:8101–8110.
70. Desoucrs C, Bribier A, Chabre-Bessa C, Ayinde D, Rice G, Crow Y, Yatim A, Schwartz O, Laguerre N, Benkirane M: SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T cells. Retrovirology 2012, 9:834.
71. Holdren J, Littman DR, Chenchik A, Chenchik A, Yang Y, Han ED: Human SAMHD1 restricts HIV-1 and HIV-2 replication in CD4+ T cells. Proc Natl Acad Sci USA 2014, 111:11602–11607.
72. Crow YJ: Out of Africa: what can we learn from the Aicardi-Goutieres Syndrome gene AGS1 locus. Nat Immunol 2014, 15:1476–1484.
73. Deschamps AD, Regalado-Magadan AS, Snegelkou B, Lee-Kirsch MA, Lieberman J: The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010, 11:1005–1013.
74. Zahour MA, Xue G, Sato H, Murakami T, Takeshima SN, Aida Y: HIV-1 Vpr Induces Interferon-Stimulated Genes in Monocytes-Derived Macrophages. PLoS One 2014, 9:e906418.
75. Lindsey RS, Fregosi D, McCoy CC, Nansen PA, Malik HS, Errmann M: The ability of primate lentiviruses to degrade the monocytic restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 2012, 11:194–204.
76. Hrecco K, Hao C, Gierzewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Fleuens L, Walshup NM, Skowronski J: Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474:658–661.
77. Laguette N, Sobhian B, Casartelli N, Ringear M, Chable-Bessa C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M: SAMHD1 is the dendritic-myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474:654–657.
78. Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT, Wight Colgyp, Dreaux H, Sigaux F, Juedde JD, Cotgreave JT, Tiittas M, Cohen DR, Henderson SJ, Ross MT, Bentley D, Hillmen P, Pettitt A, Rehwinkel J, Knight SJ, Taylor JC, Crow YJ, Benkirane M, Schul A: SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 2014, 123:1021–1031.
79. Rice G, Bond J, Aspu A, Brunette RL, Manfield IW, Caim IM, Fuller JC, Jackson RN, Lamb T, Briggs TA, Ali M, Goldin H, Couthard LR, Aebly A, Attard-Montalto SP, Bertin E, Bodermer C, Brockmann K, Brueton LA, Cory PC, Desguerre I, Fazzi E, Desguerre I, Fazzi E, Corry PC, Desguerre I, Fazzi E, Cazorla AG, Gener B, Hamel BC, Heiberg A, Hunter M, von der Knaap MS, Kumar R, Lagace L, et al: Mutations involved in Aicardi-Goutieres Syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009, 41:829–832.
80. Berger A, Sommer AF, Zwarg J, Hanmdorf M, Welzel K, Eslly N, Pantis S, Reuter A, Ramos J, Jastiani A, Mulder LC, Fernandez-Semsa A, Rutsch F, Simon V, Konig R, Flory E: SAMHD1 deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog 2011, 7:e1002425.
81. Manel N, Hogstad B, Wang Y, Levy DE, Newnham D, Littman DR: A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Cell 2011, 144:214–227.
82. Pertel T, Reinhard C, Luban J: Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type I interferon. Retrovirology 2011, 8:49.
83. Puigdomenech I, Casartelli N, Porrot F, Schwartz O: SAMHD1 restricts HIV-1 cell-to-cell transmission and limits immune detection in monocyte-derived dendritic cells. J Virol 2013, 87:2846–2856.
Cowan FM, Cox H, D’Arrigo S, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007, 81:713–725.

90. Stetson DB, Ko JS, Heidmann T, Medzhitov R: TreX1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587–598.

91. Esnault C, Millot J, Schwartz O, Heidmann T: Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res 2006, 34:1522–1531.

92. Zhao K, Du J, Han X, Goodier JL, Li P, Zhou X, Wei W, Evans SL, Li L, Zhang W, Cheung LE, Wang G, Kazazian HH Jr, Yu XF: Modulation of LINE-1 and Alu/SVA retrotransposition by Aicardi-Goutieres syndrome-related SAMHD1. Cell Rep 2013, 4:1108–1115.

93. Hasan M, Yan N: Safeguard against DNA sensing: the role of TREX1 in HIV-1 infection and autoimmune diseases. Front Microbiol 2014, 5:193.

94. Ambrose Z, Lee K, Ndjomou J, Xu H, Oztop I, Matous J, Takemura T, Unutmaz D, Engelman A, Hughes SH, KewalRamani VN: Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol 2012, 86:4708–4714.

95. Tang S, Murakami T, Agresta BE, Campbell S, Freed EO, Levin JG: Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol 2001, 75:9357–9366.

96. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, Greene WC: IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 2014, 343:428–432.

97. Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, Tengchuan J, Laustsen A, Hansen K, Ostergaard L, Fitzgerald KA, Xiao TS, Mikkelsen KS, Mogensen TH, Paludan SR: IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc Natl Acad Sci U S A 2013, 110:E4571–E4580.

98. Duggal NK, Ennerman M: Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol 2012, 12:687–695.

99. de Silva S, Planelles V, Wu L: Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells. PLoS One 2012, 7:e35385.

doi:10.1186/s12977-014-0117-5
Cite this article as: Blondot et al.: How SLX4 cuts through the mystery of HIV-1 Vpr-mediated cell cycle arrest. Retrovirology 2014 11:117.